Min had her Ph.D. training in cancer biology from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences and joined Dr. Ari Melnick’s lab in 2016 after graduation to study the role of CARD11-BCL10-MALT1 complex and the targeted therapy in ABC-DLBCL, using biochemistry, cellular and genetically engineered mouse models. The goal is to elucidate the critical role of aberrant signaling pathways in DLBCL and provide potential therapeutic targets for B cell lymphomas.